Aitia
Jean-Michel Gries is a highly experienced executive in the pharmaceutical and biotechnology sectors, currently serving as President and COO of Aitia since May 2021 and as Chairman of the Scientific Advisory Board and Chief R&D Officer at Kodikaz Therapeutic Solutions, Inc. since 2019. Gries has held notable leadership roles including President & Head of Research at Hengenix Biotech from August 2021 to September 2023, and VP & SBU Leader at Parexel, managing global business unit operations with a significant team. Additional experience includes senior roles at Covance, Alcon, Paramount BioSciences, Immunetrics, and Roche, with a proven track record in research and development, strategic management, and drug development. Educational credentials include a PhD in Applied Mathematics & Pharmacokinetics and an MBA in finance and entrepreneurial leadership from prestigious institutions.
This person is not in any teams
This person is not in any offices
Aitia
1 followers
Aitia is the leader in the application of Causal AI and Digital Twins to discover the next generation of breakthrough drugs. By leveraging the convergence of multi-omic patient data, high-performance computing, and causal learning and AI, Aitia is revealing the hidden biological mechanisms of disease to create Digital Twins of disease in oncology,neurodegenerative disorders, and immunology. Gemini Digital Twins are being used today to discover novel therapies and accelerate R&D in multiple myeloma, prostate cancer, Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease, with several more in development. Aitia’s partners include seven of the top ten pharmaceutical companies, leading academic research and medical centers, medical societies, leading multi-omic data companies, and patient advocacy groups globally.